Nancy A. Simonian - Apr 1, 2022 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Role
President & CEO, Director
Signature
/s/ Nancy Simonian
Stock symbol
SYRS
Transactions as of
Apr 1, 2022
Transactions value $
-$65,949
Form type
4
Date filed
4/4/2022, 05:02 PM
Previous filing
Mar 4, 2022
Next filing
May 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SYRS Common Stock Tax liability -$65.9K -58.9K -7.83% $1.12 693K Apr 1, 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares used to cover tax withholding on a Restricted Stock Unit release.
F2 Includes 129,117 shares of common stock released from the Restricted Stock Unit award reported on a Form 4 dated February 14, 2019.